Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized dosing of FOLFIRINOX in pancreatic cancer patients
2024-510576-21-00Phase 2Authorised
- Sponsor
- Catharina Ziekenhuis
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fluorouracil in pancreatic cancer (PC) (2 arms), sponsored by Catharina Ziekenhuis. Primary endpoints: Percentage of patients on standard BSA-dosed 5-FU achieving target 5-FU AUC within two cycles and Percentage of patients on 5-FU MIPD achieving target 5-FU AUC within two cycles. Planned start Jul 2024; status: authorised.
02
Drugs
fluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2024-510576-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510576-21-00.